Catalent

Catalent’s offering in the field of drug delivery is vast and spans oral, inhalable and injectable routes, and others. It is a development, delivery and supply partner with a large range of solutions for small molecules and biotherapeutics, including numerous proprietary drug delivery technologies.

Headquarters
Catalent Pharma Solutions Inc
14 Schoolhouse Rd
Somerset
Franklin Township
NJ 08873
United States

Phone / Contact

T: +1 732 537 6200

Articles by Catalent

INDUSTRIALISATION

ARCUS^®: A COMMERCIALISED TECHNOLOGY ENABLING HIGH-DOSE, HIGHLY RESPIRABLE POWDERS

Alan Watts and Michael Tauber, discuss the requirements and benefits of using spray-dried powders for inhalation, and how ARCUS, used for the successfully commercialised Inbrija® dry powder inhaler, is a prime example of this technology in action.

SMART SCALING FOR SUCCESSFUL CAPSULE-BASED DRY POWDER INHALER FILLING USING DRUM TECHNOLOGIES

Carolyn Berg, William Chin and Patrick Goncalves discuss the considerations for filling capsules for dry powder inhalers across the various stages of clinical trials and commercialisation, and how to tackle the challenges of scaling up filling processes.

NASAL DELIVERY – A GALAXY NOT SO FAR AWAY… A BRIEF MARKET HISTORY OF THE NASAL DELIVERY LANDSCAPE

Mark Ignaczak provides an insight into the history of nasal drug delivery and looks at the advantages of the nasal delivery route.

OPTIMA COVID-19 VACCINE FILLING SYSTEM DELIVERED TO CATALENT IN THE US

Optima has delivered a second vial filling system to Catalent's biologics facility in Bloomington, IN, US, to be used initially for the filling of a vaccine candidate to fight covid-19 (SARS-CoV-2).

Catalent Responds to the Global Outbreak of COVID-19

Catalent has noted that many governments of the countries where it operates have recognised its work as essential meaning all Catalent operating facilities remain open. The company also said it was working with several customers on COVID-related antivirals, vaccines, and treatments for symptoms and effects of the disease.

SELECTING OPTIMAL FORMULATION TECHNOLOGY FOR BETTER TREATMENT

Stephen Tindal provides reviews strategies for oral formulation selection which can lower attrition rates, and therefore development costs and time to market.

WHAT DO CUSTOMERS NEED IN ORAL DOSE DEVELOPMENT?

Chris Halling describes the translation of a drug design concept through to the development of an oral dosage form that satisfies the needs of the manufacturer, physicians and patients.

Dr Carole Evans

QUALITY BY DESIGN IN INHALATION PRODUCT DEVELOPMENT

Carole Evans and Lei Mao explore the application and principles of quality by design in the development, manufacture and commercialisation of inhaled pharmaceutical products.

Top